Doxorubicin Withdrawn Phase 1 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01333423Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
NCT00074139Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer